Dynamic Nomogram for Predicting Pacemaker Implantation Following Transcatheter Aortic Valve Replacement

2021 ◽  
Author(s):  
Vien T. Truong ◽  
Daniel Beyerbach ◽  
Wojciech Mazur ◽  
Matthew Wigle ◽  
Akhil Pallerla ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Transcatheter Aortic Valve Replacement ◽  
Pacemaker Implantation ◽  
Transcatheter Aortic Valve

scholarly journals SURVIVAL AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT WITH OR WITHOUT PACEMAKER IMPLANTATION

2021 ◽  
Vol 77 (18) ◽  
pp. 399
Author(s):  
Grzegorz Jarosinski ◽  
Marek Jasinski ◽  
Marek Deja ◽  
Andrzej Ochala ◽  
Danuta Loboda ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Transcatheter Aortic Valve Replacement ◽  
Pacemaker Implantation ◽  
Transcatheter Aortic Valve

The JenaValve pericardial transcatheter aortic valve replacement system to treat aortic valve disease

2021 ◽  
Author(s):  
Thomas Poschner ◽  
Paul Werner ◽  
Alfred Kocher ◽  
Guenther Laufer ◽  
Francesco Musumeci ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Transcatheter Aortic Valve Replacement ◽  
Pacemaker Implantation ◽  
Limited Data ◽  
Transcatheter Aortic Valve ◽  
Paper Clip ◽  
Replacement System

Transcatheter aortic valve replacement is a valuable alternative technique to surgery and the spectrum of therapy continues to evolve. The JenaValve Pericaridal transcatheter aortic valve replacement System allows prosthesis fixation in a native, noncalcified aortic annulus with a unique paper clip-like anchorage mechanism. The low rate of paravalvular leakage and permanent pacemaker implantation emphasizes the further widespread use of the JenaValve – despite the limited data available. In May 2021, a CE mark for the transfemoral implantation in both aortic regurgitation and aortic stenosis was granted. However, no data have been published so far. The ongoing ALIGN trials are expected to provide the pending long-term data.

Identifying patients likely to be readmitted after transcatheter aortic valve replacement

Heart ◽  
2019 ◽  
Vol 106 (4) ◽  
pp. 256-260 ◽  
Author(s):  
Andrew Goldsweig ◽  
Herbert David Aronow
Keyword(s):  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Transcatheter Aortic Valve Replacement ◽  
Left Ventricular Systolic Dysfunction ◽  
Pacemaker Implantation ◽  
Left Ventricular ◽  
Routine Practice ◽  
Heart Team ◽  
Transcatheter Aortic Valve

Hospital readmission following transcatheter aortic valve replacement (TAVR) contributes considerably to the costs of care. Readmission rates following TAVR have been reported to be as high as 17.4% at 30 days and 53.2% at 1 year. Patient and procedural factors predict an increased likelihood of readmission including non-transfemoral access, acute and chronic kidney impairment, chronic lung disease, left ventricular systolic dysfunction, atrial fibrillation, major bleeding and prolonged index hospitalisation. Recent studies have also found the requirement for new pacemaker implantation and the severity of paravalvular aortic regurgitation and tricuspid regurgitation to be novel predictors of readmission. Post-TAVR readmission within 30 days of discharge is more likely to occur for non-cardiac than cardiac pathology, although readmission for cardiac causes, especially heart failure, predicts higher mortality than readmission for non-cardiac causes. To combat the risk of readmission and associated mortality, the routine practice of calculating and considering readmission risk should be adopted by the heart team. Furthermore, because most readmissions following TAVR occur for non-cardiac reasons, more holistic approaches to readmission prevention are necessary. Familiarity with the most common predictors and causes of readmission should guide the development of initiatives to address these conditions proactively.

Sign in / Sign up

Export Citation Format

Share Document